AdipoGen Life Sciences

FNDC4 (rec.) (untagged)

CHF 215.00
In stock
AG-40B-0124-C01010 µgCHF 215.00
AG-40B-0124-C05050 µgCHF 780.00
More Information
Product Details
Synonyms Fibronectin Type III Domain-containing Protein 4; Fibronectin Type III Repeat-containing Protein 1
Product Type Protein
Source/Host E. coli

FNDC4 (extracellular domain, human (aa 45-167) / mouse (aa 41-163)) is untagged. FNDC4 extracellular domain has 100% identity between human, mouse, rat, dog and monkey.

Crossreactivity Dog
MW ~16kDa
Purity ≥95% (SDS-PAGE)
Endotoxin Content <0.01EU/μg purified protein (LAL test; Lonza).
Concentration After reconstitution:
for 10µg size: 0.1mg/ml
for 50µg size: 1 mg/ml
Reconstitution 10µg size: Reconstitute with 100µl sterile water.
50µg size: Reconstitute with 50µl sterile water.
Formulation Lyophilized. Contains PBS.
Other Product Data

Uni-Prot link Q9H6D8: FNDC4

Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
PBS containing at least 0.1% BSA should be used for further dilutions.
Use/Stability Stable for at least 6 months after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF

Irisin is a recently described exercise-induced hormone secreted by skeletal muscle in mice and humans. Irisin activates beige fat cells (beige cells have a gene expression pattern distinct from either white or brown fat and are preferentially sensitive to the polypeptide hormone irisin). Irisin is cleaved from the type I membrane protein FNDC5 and improves systemic metabolism by increasing energy expenditure. FNDC4 is an ortholog of FNDC5 with 50% identity and 86% similarity compared to Irisin. FNDC4 as well as FNDC5 are extremely well conserved between species. The human FNDC4 gene is highly enriched in liver, brain tissue and adipocytes. FNDC4 is a factor with direct therapeutic potential in inflammatory bowel disease and possibly other inflammatory diseases.

Recently, a new role of FNDC4 as a hepatokine has been published. Liver primarily controls the circulating levels of FNDC4 showing tight correlation with insulin sensitivity. In addition, a new orphan adhesion G protein-coupled receptor 116 (GPR116) has been identified as a receptor of FNDC4 in white adipose tissue (WAT), thereby establishing an endocrine FNDC4-GPR116 axis in the control of systemic glucose homeostasis. Moreover, the FNDC4-GPR116 axis is impaired in diabetic patients and therapeutic injections of recombinant Fc-FNDC4 into pre-diabetic mice corrected pre-diabetic hyperglycemia.

Product References
  1. FNDC4, a novel adipokine that reduces lipogenesis and promotes fat browning in human visceral adipocytes: G. Fruehbeck, et al.; Metabolism 108, 154261 (2020)
  2. Orphan GPR116 mediates the insulin sensitizing effects of the hepatokine FNDC4 in adipose tissue: A. Georgiadi, et al.; Nature Commun. 12, 2999 (2021)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.